Bayer Healthcare Company Profile

✉ Email this page to a colleague

BAYER HEALTHCARE has twenty-nine approved drugs.

There are twenty-eight US patents protecting BAYER HEALTHCARE drugs. There is one tentative approval on BAYER HEALTHCARE drugs.

There are four hundred and twenty-four patent family members on BAYER HEALTHCARE drugs in fifty-nine countries and forty-nine supplementary protection certificates in seventeen countries.

International Patents:	424
US Patents:	28
Tradenames:	24
Ingredients:	14
NDAs:	29
Patent Litigation for Bayer Healthcare:	See patent lawsuits for Bayer Healthcare

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Bayer Healthcare	NUBEQA	darolutamide	TABLET;ORAL	212099-001	Jul 30, 2019		RX	Yes	Yes	11,046,713	⤷ Try a Trial		Y		⤷ Try a Trial
Bayer Healthcare Llc	CLARITIN HIVES RELIEF	loratadine	TABLET;ORAL	019658-003	Nov 19, 2003		OTC	Yes	Yes		⤷ Try a Trial				⤷ Try a Trial
Bayer Healthcare	LAMPIT	nifurtimox	TABLET;ORAL	213464-001	Aug 6, 2020		RX	Yes	No		⤷ Try a Trial				⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Bayer Healthcare Llc	MYCELEX	clotrimazole	CREAM;TOPICAL	018183-001	Approved Prior to Jan 1, 1982	3,839,573	⤷ Try a Trial
Bayer Healthcare Llc	SHADE UVAGUARD	avobenzone; octinoxate; oxybenzone	LOTION;TOPICAL	020045-001	Dec 7, 1992	4,387,089	⤷ Try a Trial
Bayer Healthcare Llc	SHADE UVAGUARD	avobenzone; octinoxate; oxybenzone	LOTION;TOPICAL	020045-001	Dec 7, 1992	4,522,807	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
3106463	2020004	Norway	⤷ Try a Trial	PRODUCT NAME: LAROTREKTINIB OG/ELLER FARMASOEYTISK AKSEPTABLE SALTER DERAV, SAERLIG LAROTREKTINIBSULFAT INKLUDERT LAROTREKTINIBHYDROGENSULFAT; REG. NO/DATE: EU/1/19/1385 20191018
2493858	132020000000064	Italy	⤷ Try a Trial	PRODUCT NAME: DAROLUTAMIDE(NUBEQA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1432, 20200330
2493858	20C1028	France	⤷ Try a Trial	PRODUCT NAME: DAROLUTAMIDE Y COMPRIS SES SELS PHARMACEUTIQUEMENT ACCEPTABLES ET SES ESTERS COUVERTS PAR LE BREVET DE BASE; REGISTRATION NO/DATE: EU/1/20/1432/001 20200330
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.